Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.060 | GeneticVariation | disease | LHGDN | Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. | 14706653 | 2004 | ||||
|
0.060 | GeneticVariation | disease | BEFREE | SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. | 15868370 | 2005 | ||||
|
0.060 | GeneticVariation | disease | BEFREE | Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection. | 25717047 | 2015 | ||||
|
0.060 | GeneticVariation | disease | BEFREE | Suppressor of cytokine signaling 3, myxovirus resistance protein and osteopontin gene polymorphisms may influence the therapeutic response in patients with chronic hepatitis C, and an association with IL28 might increase the power to predict sustained virologic response. | 24212839 | 2013 | ||||
|
0.060 | GeneticVariation | disease | BEFREE | OPN promoter region SNP at nt -433 may be a useful marker reflecting hepatitis activity in chronic hepatitis C patients. | 14706653 | 2004 | ||||
|
0.060 | GeneticVariation | disease | BEFREE | Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4. | 23400862 | 2013 | ||||
|
0.060 | Biomarker | disease | LHGDN | SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. | 15868370 | 2005 | ||||
|
0.060 | AlteredExpression | disease | BEFREE | It can be concluded that SNP in the promoter region of OPN at nt -443 and serum OPN protein level are predictors of response to the efficacy of peg-IFN-α2b-ribavirin therapy in Egyptian patients with chronic hepatitis C. | 22836041 | 2012 |